Tero Aittokallio

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data (2015)

Bioinformatics

Mpindi JP, Swapnil P, Dmitrii B, Jani S, Saeed K, Wennerberg K, Aittokallio T, Ostling P, Kallioniemi O

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Patient-derived prostate cancer cells for piloting of drug sensitivity and resistance testing (2015)

BJU International

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Ostling P, af Hallstrom TM

(O2 Muu julkaisu )

Dasatinib and everolimus show synergistic growth inhibition with paclitaxel in an ovarian granulosa cell tumor model (2015)

Cancer Research

Haltia UM, Andersson N, Yadav B, Kulesskiy E, Farkkila A, Riska A, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M

(O2 Muu julkaisu )

Pro-apoptotic functions of AMPK revealed by Myc (2015)

Molecular Cancer Research

Haikala HM, Marques E, Eskelinen V, Viheriaranta-Nieminen A, Saarikoski S, Nevalaita L, Kovanen P, Heikkila P, Leidenius M, Laajala D, Aittokallio T, Munne P, Klefstrom J

(O2 Muu julkaisu )

Prediction of human population responses to toxic compounds by a collaborative competition (vol 33, pg 933, 2015) (2015)

Nature Biotechnology

Eduati F, Mangravite LM, Wang T, Tang H, Bare JC, Huang RL, Norman T, Kellen M, Menden MP, Yang JC, Zhang X, Zhong R, Xiao GH, Xia MH, Abdo N, Kosyk O, Friend S, Dearry A, Simeonov A, Tice RR, Rusyn I, Wright FA, Stolovitzky G, Xie Y, Saez-Rodriguez J, Jaiswal A, Poso A, Chheda H, Kaur I, Tang J, Mpindi JP, Wennerberg K, Krasnogor N, Kaski S, Aittokallio T, Hintsanen P, Khan SA

(O2 Muu julkaisu )

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML (2015)

Blood

Karjalalainen R, Pemovska T, Majumder MM, Yadav B, Tang J, Kontro M, Gjertsen B, Parsons A, Suvela M, Porkka K, Aittokallio T, Kallioniemi O, Wennerberg K, Knowles J, Heckman C

(O2 Muu julkaisu )

Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling (2015)

Scientific Reports

Otto Kauko, Teemu Daniel Laajala, Mikael Jumppanen, Petteri Hintsanen, Veronika Suni, Pekka Haapaniemi, Garry Corthals, Tero Aittokallio, Jukka Westermarck, Susumu Y. Imanishi

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

What is synergy? The Saariselka agreement revisited (2015)

Frontiers in Pharmacology

Tang J, Wennerberg K, Aittokallio T

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors (2015)

Cancer Research

Gautam P, Karhinen L, Szwajda A, Jha SK, Yadav B, Aittokallio T, Wennerberg K

(O2 Muu julkaisu )

Identification of drug candidates and repurposing opportunities through compound-target interaction networks (2015)

Expert Opinion on Drug Discovery

Anna Cichonska, Juho Rousu, Tero Aittokallio

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data (2015)

Patient-derived prostate cancer cells for piloting of drug sensitivity and resistance testing (2015)

Dasatinib and everolimus show synergistic growth inhibition with paclitaxel in an ovarian granulosa cell tumor model (2015)

Pro-apoptotic functions of AMPK revealed by Myc (2015)

Prediction of human population responses to toxic compounds by a collaborative competition (vol 33, pg 933, 2015) (2015)

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML (2015)

Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling (2015)

What is synergy? The Saariselka agreement revisited (2015)

Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors (2015)

Identification of drug candidates and repurposing opportunities through compound-target interaction networks (2015)